Sales revenue rose to RON330 million from RON318.9 million in 2014 while the main categories of expenses (raw material, consumables, and exploitation expenses) rose to RON118.8 million and RON112 million, respectively.
The company said in a statement to the Bucharest Stock Exchange that it has continued its consolidation on the Romanian pharmaceutical market.
Although the market fell for the first time in the past years, both by value (0.87%) and by volume (4.74%), Antibiotice posted the highest growth in the top of the 15 largest companies. Thus, it reached a market share of 2.45% by value and 5.56% by sales volume.
Antibiotice is majority-owned by Romania’s Health Ministry, with a 53.02% stake, while regional investment fund SIF Oltenia (SIF5. RO) holds a 10.1% stake.